Price controls for medicine are proven to work, based on single payer European systems. They cost cheaper and provide better outcomes than the US system.
Yet here we are.
Price controls for medicine are proven to work, based on single payer European systems. They cost cheaper and provide better outcomes than the US system.
Yet here we are.
https://www.investopedia.com/terms/f/free_rider_problem.asp
Outcome differences are due more to public health and social factors like obesity. Expensive drugs or lack thereof have only a tiny impact at the population level.
Europeans aren’t free riding; they’re paying a reasonable rate for these goods while Americans are shouldered with extraction of revenue for pharma profits and those inefficient (and arguably unnecessary) sales and marketing expenses.
Only two countries in the world permit marketing directly to consumers to promote pharmaceuticals: the United States and New Zealand.
But in general the traditional drug development approach of finding small molecule drugs to treat specific diseases is running out of steam. Most of the low-hanging fruit has already been picked.
It's like Private hospitals, we have them, but very few people use them as the public system is better equipped and paid for by the tax payer.
Since medicine is mostly a technological good, it lets the rest of the world freeride off America paying for much of medical R&D.
But you are correct that in those cases it can work well. Same with other monopolies like utilities.
Housing, OTOH, is always local. Low rents will discourage development which will make the real, underlying problem worse.